Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now

Cigna Drops Humana Merger, Opts For $10 Billion Buyback Strategy

Published 10/12/2023, 19:00
Updated 10/12/2023, 20:10
© Reuters.  Cigna Drops Humana Merger, Opts For $10 Billion Buyback Strategy

Benzinga - by Bibhu Pattnaik, Benzinga Staff Writer.

In a recent development in the health insurance sector, Cigna Corporation (NYSE: CI) has withdrawn from its proposed merger with Humana Inc. (NYSE: HUM).

What Happened: The deal, poised to create a colossal entity in the industry with an estimated $140 billion, fell through due to disagreements over financial terms.

With the merger off the table, Cigna is redirecting its strategy towards smaller, targeted acquisitions, reports The Wall Street Journal.

These acquisitions, described as "bolt-on," signify a tactical pivot for the company. Initial discussions about Cigna acquiring Humana in a significant cash-and-stock transaction surfaced last month.

However, the proposal was met with skepticism from shareholders, leading to a notable decline in Cigna's stock value. Concerns centered on the proposed use of Cigna's stock in the transaction.

Rather than pursuing the acquisition, Cigna is planning a substantial stock buyback program. This initiative involves an additional $10 billion in stock repurchases, elevating the planned buybacks to $11.3 billion.

Also Read: This Is What Whales Are Betting On Cigna Group

Despite abandoning the merger, Cigna has maintained a positive outlook on the potential benefits of a partnership with Humana, especially in improving healthcare access and reducing consumer costs.

Despite the current administration's stringent approach to mergers and acquisitions, Cigna remains confident that a deal with Humana would have been viable from a regulatory standpoint.

The company intends to use a significant portion of its discretionary cash flow for share buybacks in the coming year, including repurchasing at least $5 billion of common stock by mid-2024.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

As Cigna explores the sale of its Medicare Advantage business, the collapse of the Humana deal leaves it potentially on the sidelines of a vital and growing insurance market segment.

After its $54 billion acquisition of Express Scripts Holding, Cigna has emerged as a key player in pharmacy benefits and is expanding its Evernorth health services unit.

Related stocks such as UnitedHealth Group Inc. (NYSE: UNH) and Elevance Health Inc (NYSE: ELV), along with ETFs like the Health Care Select Sector SPDR Fund (NYSEARCA: XLV) and the iShares U.S. Healthcare ETF (NYSEARCA: IYH), often see movements in response to significant industry developments like this.

Now Read: Here's How Much You Would Have Made Owning Cigna Group Stock In The Last 10 Years

This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Photo: Shutterstock

© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.